GAITHERSBURG, Md., April 8, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the Goldman Sachs Recovery Inoculated: The Current Outlook for COVID-19 Vaccines, Treatments, Testing and the Economy virtual conference. Novavax' COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Fireside chat details:
Date:	Tuesday, April 13, 2021
Time:	2:30 – 3:20 p.m. Eastern Time (ET)
Panel title:	COVID-19 Vaccines – Staying Ahead of the Curve
Novavax participant:	Vivek Shinde, M.D., M.P.H., Vice President, Clinical Development More on Marylandian Steward's Plumbing Sponsors the 2025 Samson Challenge, Bringing Community, Fitness, and Fun Together in Albuquerque Maryland: Poultry Farmers Urged to Practice Enhanced Biosecurity 10xLaw.com Extends Employment Opportunity to Kim Kardashian DecisionPoint Technologies Accelerates Growth with Acquisition of Acuity Technologies CCHR: Involuntary Commitment Is Eugenics Repackaged as "Mental Health Care"
	This event is open to Goldman Sachs clients.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

More on Marylandian

• Q2 2025 Industry Impact Report Underscores Semiconductor Expansion, Talent Development and Sustainability Milestones
• 84 Ethiopian Churches Change Signboards to Shincheonji Church of Jesus
• BTXSGG Outlines Four-Pillar Framework to Enhance Digital Asset Security and Compliance
• NJTRX Positions for Next-Generation Asset Trading with U.S. Regulatory Framework
• Poncho Tha Popstar: The West's Next King

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
[email protected]

Solebury Trout
Jennifer Porcelli | 646-378-2962
[email protected]

Media
Laura Keenan | 410-419-5755
Amy Speak | 617-420-2461
[email protected]

SOURCE Novavax, Inc.

Related Links

http://www.novavax.com

---

Show All News | Report Violation